Thalassemia and malignancies: Updates from the literature

被引:1
|
作者
Hodroj, Mohammad Hassan [1 ]
Taher, Ali [1 ,2 ]
机构
[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Hematol & Oncol, Beirut, Lebanon
[2] Amer Univ Beirut, Dept Internal Med, Div Hematol & Oncol, Med Ctr, Cairo St, Beirut 11072020, Lebanon
关键词
malignancies; non-transfusion-dependent thalassemia; thalassemia; transfusion-dependent thalassemia; BETA-THALASSEMIA; HEPATOCELLULAR-CARCINOMA; HEMATOLOGICAL MALIGNANCIES; CELL-MIGRATION; IRON OVERLOAD; CANCER; INTERMEDIA; DISEASE; LEUKEMIA; PATIENT;
D O I
10.1111/nyas.15061
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Thalassemia management has undergone significant development with the advancement in iron chelation therapy, which has led to a prolonged life expectancy. This has been accompanied by the emergence of several new morbidities and chronic diseases, including cancer. Over the years, multiple cases of solid and hematologic malignancies in thalassemia patients have been reported in the literature, with no clear mechanism for the development of cancer in these patients despite a number of potential mechanisms. However, the results of many studies have been contradictory regarding the risk of development of malignancies in thalassemia. The present review aims to discuss the available data on cancer and thalassemia in the literature, with the latest updates regarding possible malignancy development mechanisms, risks, and the most commonly reported types.
引用
收藏
页码:14 / 20
页数:7
相关论文
共 50 条
  • [41] CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
    Huang, Ruihao
    Wen, Qin
    Zhang, Xi
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [42] Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
    Ji-nuo Wang
    Tianning Gu
    Yongxian Hu
    He Huang
    Experimental Hematology & Oncology, 11
  • [43] CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
    Ruihao Huang
    Qin Wen
    Xi Zhang
    Journal of Hematology & Oncology, 16
  • [44] Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
    Jing-Zhou Hou
    Jing Christine Ye
    Jeffrey J. Pu
    Hongtao Liu
    Wei Ding
    Hong Zheng
    Delong Liu
    Journal of Hematology & Oncology, 14
  • [45] Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
    Wang, Ji-Nuo
    Gu, Tianning
    Hu, Yongxian
    Huang, He
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [46] Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting
    Guangcai Zhong
    Ran Kong
    Shi Feng
    Cong Wang
    Qingbo Hao
    Weilin Xie
    Xiangxiang Zhou
    Journal of Hematology & Oncology, 17
  • [47] Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
    Hou, Jing-Zhou
    Ye, Jing Christine
    Pu, Jeffrey J.
    Liu, Hongtao
    Ding, Wei
    Zheng, Hong
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [48] Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment
    Mody, Mayur D.
    Saba, Nabil F.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (01)
  • [49] Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies
    Lesniak, Maria
    Lipniarska, Justyna
    Majka, Patrycja
    Lejman, Monika
    Zawitkowska, Joanna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (23)
  • [50] Primary Exertional Headache: Updates in the Literature
    Rashmi B. Halker
    Bert B. Vargas
    Current Pain and Headache Reports, 2013, 17